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ABSTRACT
Objective: To explore inhibition effects of veliparib as PARP inhibitor combined doxorubicin
for BEL-7404 proliferation of human liver cancer cell line. Methods: BEL-7404 was taken as
the object of study and conventional culture was performed. It wastreated by doxorubicin and
(or) veliparib after 24 h. Cell proliferation rate was detected by four methyl thiazolyl tetrazolium
(MTI) assay, cell apoptosis was measured with annexin V-FITC/PI double staining method by
flow cytometry, DNA damage degree evaluation by single cell gel electrophoresis assay, and
cytosolic C levels of the mitochondrial and cytosol by polyacrylamide gel electrophoresis (Western
blotting). Results: Cell proliferation rate of doxorubicin combined veliparib group was lower than
that of the control group and doxorubicin alone treated group significantly (P<O.OI), the apoptosis
rate was significantly higher than that of the control group and doxorubicin alone treated group
(P<O.05). At the same time, DNA damage level of doxorubicin combined with veliparib group was
significantly higher than doxorubicin alone treatment group and the control group (P<O.OI), and
cytochrome C in the cytosol was significantly higher than that of control group and doxorubicin
alone treated group (P<O.OI). Conclusions: Veliparib, PARP inhibitor could inhibit PARP
activity, block tumor cell DNA repair, and have significant sensitizing effect for hepatocellular
carcinoma cell line BEL-7404 treated with doxorubicin. This might provide a new target for
clinical treatment of hepatic carcinoma.
1. Introduction
Doxorubicin (also named as adriamycin, ADR) has broad
antitumor effect as the typical DNA intercalating agent,
which is often used as first-line anticancer drugs in
treatment of acute leukemia, malignant lymphoma, multiple
myeloma, breast cancer, osteosarcoma, soft tissue sarcoma
and liver canceritl. Research showed that ADR was a kind
of the cell cycle non-specific drugs, which could combine
with the DNA topoisomerase II, strain close re-process
of bridge fracture instantly double chain enzyme caused
by the inhibition of topoisomerase II. And initiatation of
programmed cell apoptosis is not easy due to the recovery
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of the double strand breaks generated DNA replication and
transoriptionlz.al, ADR is considered to be one of the most
effective chemotherapy for treatment of liver cancer, which
reaches the highest concentration in the liver and stay
longer in the body. The pharmacokinetic characteristics are
very conducive to the treatment of liver cancer. Research
proves that it's markedly effective and effective rate is
more than 10%-30%, which could make the liver cancer
issue shrink or fade. However, it is still limited in the
clinical application due to the adverse reactions, such as
hair loss, bone marrow suppression and cardiac toxicity, et
al. Therefore it is of great scientific significance to explore
other factors related to the effect of anti tumor.
Poly adenosine double phosphate ribose polymerase
(PARI') is a catalytic ribozyme for catalytic poly ADP ribose
existing in eukaryotic cells, which plays the key role in
DNA damage repair. It could recognize and bind the DNA
chain fracture, then recruitment ADP, the histone and
the auxiliary factor related to DNA damage repair, then
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complete DNA repair through the adjustment process of a
series of catalysislsl, The clinical studies have demonstrated
that the inhibitor of PARP could initiate DNA damage repair
by inhibition of anti tumor drugs, and lead to the apoptosis
of tumor cells. Therefore, as a kind of the clinical treatment
for cancer around PARP, those PARP inhibitors combined
with chemotherapy or radiotherapy can repair the process
of DNA damage and enhance the sensitivity of tumor cells.
And then further it can reduce the clinical side effects of
by reducing chemotherapy or the radiation dose[5,61. Large
number of clinical trials hve found that PARP inhibitors
have small toxic and side effect, while it is effective and
well tolerated chemotherapy or radiotherapy sensitizer, so it
has broad prospects for cancer treatment.
Liver cancer is a major threat to human health in the
world, ranked sixth in the global incidence of malignant
tumors. New cases is more than 626 000 every year, about
half of whom occurrs in our country and the mortality rate
ranks the second in tumor mortality. The majority of liver
cancer patient lost the best time for treatment at the time
of diagnosis due to surgical contraindication or transform.
Chemotherapy is the main treatment measurement for
them, while its efficacy is limited to drug resistance and
chemotherapy side effects. Therefore it is necessary to
explore chemotherapeutic drugs of the efficient, targeting
and low toxicity for liver cancer. Veliparib is a kind of
efficient PARP inhibitor and is the representative of the
third generation. Research showed that veliparib used
alone is tolerated well and activity is high in ovarian cancer
patients carrying the mutation gene of BRCAm Experiment
of the mouse breast tumor model showed that tumor
volume is significantly significant reduced combined with
veliparib, compared with chemotherapy alonelsl, This study
is designed to investigate the inhabition effect of veliparib
combination with ADR on the proliferation of hepatocellular
carcinoma cell lines BEL-7404. This study aims to observe
DNA damage and cytochrome c release by comet assay and
Western blotting methods, explore its possible mechanism
and provide the experimental basis for the clinical treatment
of liver cancer.
2. Materials andmethods
2.1. Cell lines and the reagents
Human liver cancer cell line BEL-7404 was purchased
from America type culture collection. Fetal bovine serum,
RPMI1640 was from American product of Gibco Company.
Injection of doxorubicin was from pfizer Pharmaceutical
(Wuxi) Co.ltd. Veliparib was from America Selleck Company.
Mitochondria/cytosolic protein extraction, isolation kit
was provided by the biotechnology research Institute of
Biyuntian from Jiangsu. BCA protein assay kit was from
Wuhan boster Biological Engineering Co., Ltd. (AROI46).
Annexin V-FITCIPI double staining cell apoptosis detection
kit was from Nanjing keygen biotech development Co., Ltd.
production (KGA105), methylthiaLzolyItetraLzolium (MTT)
were from America Sigma-Aldrich Company. Mouse anti
human ~ -actin antibody, mouse anti human cytochrome
C antibody and Goat anti mouse two anti were from Nanjing
Bioworld Biotechnology Co.ltd. Other common chemicals
were analytically pure made in China.
2.2. Method
2.2.1. Cell culture
EL-7404 cell were cultured with 10% fetal bovine serum, 50
UlmLpenicillin and RPMI1640 with 50 p.g/mL streptomycin,
and cultured with 5%CO2, 37 'C in the incubator. They were
digested by 0.25% Trypsin, and passaged one day at the
proportion of 1:2.
2.2.2. MIT test
BEL-7404 cells of logarithmic growth period were selected
and made into single cell suspension and counted. 4X103
cells each hole was put into 96 well culture plate before
24 h. 5 P. g/mL ADR was made based on our preliminary
experimental results and other reports of the literature.
Cells were divided into 5 groups randomly: control group
(control)(without any treatment), ADRgroup (5 p. g/mL ADR
treatmentalone), combinedgroupofA (5 P. g/mLADR+5 P. mollL
vel iparib), combined group of B (5 P. g/mL ADR+
10 P. mollL veliparib), Group C (5 P. g/mL ADR+20 p.moll
L veliparib). 6 holes in each group were cultured for 24 h,
and added with 100 P. L MTT solution after the supernatant
discarded (final concentration was 0.05 mg/ml.). They were
cultured for 4 h at 37"C free from light, and the supernatant
was discarded. Then it was added with 150 p.L dimethyl
sulfoxide (DMSO) in each hole, the absorbance value of
Synergy 2 type multifunctional enzyme mark instrument
(A570) was read. Cell proliferation rate (%)=OD value of the
experimental group/OD value of the control group / xlOO].
2.2.3. BEL-7404 cell apoptosis analyzed by Annexin
V-FITC/PI double staining method
The single cell suspension was prepared from BEL-7404
cell of logarithmic growth period and counted, which were
seeded in 6 well culture plates, 3x106 cells each hole, 24 h
before the experiment.
Cells were treated for 24 h, and washed 2 times with pre-
cold PBS, digested by 0.25% trypsin. Cells were collected
to made cells suspension with PBS after centrifugation at
1 000 g for 5 min. After counting, 5.0x105 suspension cells
was centrifuged for 5 min, supernatant was discard, and
it was added with 500 p.L binding buffer mixture gently.
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Then it was added with 5 f1. L Annexin V-FITC and 5 f1. L
PI solution and mixed for 10 min (20-25 "C,free from light).
The apoptosis rate was detected by flow cytometry and the
detection results were analyzed by FACSC alibur software.
3. Result
3.1. Resultsofthe cellproliferation rate
3.2. Resultsofthe apoptosis rate
The cell proliferation rate of BEL-7404 was changed after
24 h treated with ADR and (or) veliparib. Compared with
the control group, *P<0.05. Compared with ADR group,
##P<O.Ol. Compared with ADRgroup, #P<0.05.
As shown in Figure 2, BEL-7404 cells were treated with
different methods after 24 h, the apoptosis was the main
form of cell early death in all treatment groups. And whether
the early apoptosis rate or late apoptosis rate, they were
significantly higher than those of the control group (P<O.01).
When veliparib and ADRwas used together (combined group
A, B and C), with the dose increased, the cell apoptotic rate
was increased, which showed Veliparib dose dependent
change,and the early and late apoptosis apoptosis rate was
higher than that in ADRgroup significantly (P<0.05).
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Figure 1. MIT test analysis.
As shown in Figure 1, the proliferation rate of BEL-7404
cells in all the treatment groups were significantly lower
than those of the control group (P<0.01). When veliparib
concentration was 5 f1. mollL, the inhibitory effect on the
proliferation rate of BEL-7404 was more significant than that
with ADR alone (P<0.05). When the veliparib concentration
was 10 f1. mollL and 20 f1. mollL, the proliferation rate
of BEL-7404 was significantly increased (P<0.01). The
proliferation rates of ADRgroup, group A, group B and group
C cell were veliparib dose-dependent.
2.2.4. Evaluation ofDNA damage degree of BEL-7404 cell
by singlecellgel electrophoresis assay
According to method of the Iiteraturelsl, by three layer
of the gel method, 3 parallel plates were prepared at each
concentration. Gel-Gel film-cell disruption-DNA selection-
electrophoresis-neutralization was performed, then
propidium iodide (PI) staining was carried out. Single cell gel
electrophoresis images were observed under a fluorescence
microscope (400 times), 25-50 cells was counted each layer,
not less than 100 cells of three layers in each group. The
comet tail length, the tail area, tail torque, tail torque arm
and olive tail of the image were calculated by CASP comet
image analysis software. In view of the olive tail moment
was a comprehensive index of DNA damage evaluation,
and it was selected as the final index for cell DNA damage
evaluation.
2.2.5. Cytochrome C proteinin mitochondrion and cytoplasm
ofBEL-7404 cell by Westemblottingdetection
Mitochondria/cytosolic protein extraction, separation
and quantitative measurement were performed according
to kit instructions. 30 f1. g was taken to measure protein
samples with protein sample buffer at the proportion of
4:1, and 95 'C water bath degeneration was carried out
for 10 min. Electrophoresis was performed 2.5 h in 15%
SDS- polyacrylamide gel, transferred to 0.45 f1. m PVDF
membrane, closed for 1 h at room temperature in 5% bovine
serum albumin buffer solution. It was washed with PBST
swing 3 times, 10 min for every time. The first antibody was
incubated at 4 "C overnight. The next day, PBST membrane
was washed 3 times, 10 min for every time. It was added with
the second antibody labeled horseradish peroxidase (HRP).
They were incubated them for 1 h, added with PBST and
washed. Then it was added with ECL sensitivity luminous
liquid, and a protein expression level was detected with
multiple function gel imaging analyzer. With ~ -actin as
equal protein control, the gray value of protein band in each
group were analyzed by gel image analysis software (Image
J).
3.3. Experimental results ofsinglecellgel electrophoresis
2.3. Statisticalprocessing
All data were presented as mean±standard deviation, the
experimental results was analyzed with SPSSl1.0 software
package. The variance homogeneity test and t test were
used between the two groups, P<0.05 showed that they had
significant difference.
As shown in Figure 3, the BEL-7404 cells were treated for
24 h, compared to the control group, DNA damage degree
of all treated group were increased significantly (P<0.01).
Treated with veliparib and ADR, BEL-7404 cell DNA damage
level was increased with veliparib dose increasing, and it
was veliparib dose dependent. Compared with ADR group,
cell DNA damage in all treated group was also increased
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significantly (P<O.05).
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4. Discussion
Figure 4. Cytochromec distribution changes of BEL-7404 cell in the
mitochondria and cytoplasm after 24 h.
Compared with the control group, *P<O.05. Compared with ADR
group, ##P<O.Ol. Compared with ADR group, #P<O.05.
PARP is an important gene in eukaryotic cells, and play
a central role in the DNA damage and repair prooessliol,
PARP-l is one of the most important members of PARP
family and a kind of ribozyme in eukaryotic cells. When
the DNA damage occurs, its conservative sequence can
combined with single or double stranded DNA rapidly
and directly, and activate DNA- protein complex form,
thereby raising more DNA damage repair factor. It can
transfer cell damage signal and complete the DNA repair
process by receptor protein poly adenosine diphosphate
glycosylation modification, self modification and poly
adenosine diphosphoric acid glycosyl hydrolase rolel-l. At
the same time, the excessive activation of PARP-l initiate
the cells apoptosis by promoting mitochondrial apoptosis
inducing factor release and the fracture of double stranded
DNA[ll]. Deletion of PARP-l can make DNA injury of tumor
cell be susceptible to chemotherapy drug, which may
involved in certain tumors occur directlylizl. In addition,
the function of PARP-l is inhibited by chemical inhibitors
or gene silencing, and which can reduce DNA damage
repair efficiency and enhance the effect of radiotherapy
or chemotherapy for some DNA damage[13J. Recently, the
application of PARP inhibitors alone achieved good effect
in the specific treatment of tumor. Bryant study found that
a PARP-l inhibitor alone could inhibit significantly the
tumor cells growth with deletion of BRCA-l and BRCA
of-2 gene in vitro experimentli-l. In vivo test, Martin found
that PARP-l inhibitors alone could inhibit the growth of
skin tumor cells[15J. In addition, the research that PARP-l
inhibitors with chemotherapy drugs for cancer treatment
has entered clinical trials, and some progress has been
made. Zhang et al found the epithelial ovarian cancer cell
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Figure 2. Change of apoptosis rate of BEL-7404 cells treated with
ADR and (or)veliparib by flowcytometry after 24 h.
Compared with the control group, **P<O.Ol. Compared with the
control group, *P<O.05. Compared with ADR group, ##P<O.Ol.
Compared with ADR group, #P<O.05.
Figure 3. DNA damage degree of BEL-7404 cell detected by single
cell gel electrophoresis assay treated with ADR and (or) veliparib for
24h.
Compared with the control group, *P<O.05. Compared with ADR
group, ##P<O.Ol.Compared with ADR group, #P<O.05.
As shown in Figure 4, BEL-7404 cells were treated for 24
h, mitochondrial C level of cytochrome in the treatment
group were lower significantly, while those in cytoplasm was
increased significantly (P<O.05). With veliparib and ADR
together, except (ADR+5 mollL veliparib) group, cytochrome
C levels of mitochondrion in the other combination group
were significantly lower than those in ADR alone treated
group (P<O.05). Cytochrome C level of intracellular in all the
combined treatment groups were significantly higher than
those of ADRalone treatment group (P<O.01).
3.4. Results ofWestern blotting
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line resistant to cisplatin exposure to PARP-l inhibitor PI34
could be against ovarian cancer cell proliferation, and the
sensitivity of cells to cisplatin increased significantly[16J.
Veliparib is a kind of PARP-l inhibitors of oral potent, and
now has entered clinical trial, and have synergistic effects
with chemotherapy drugs including temozolomide. And it
combined with radiotherapy could enhance significantly
the killing effect on tumor and had good tolerancel-l,
bioavailability in mice, cats, dogs after took them could be
reached at 92%, 61%and 72%[17].
In this study, human liver cancer cell line BEL-7404 as
the research object, to investigate the effect of veliparib
inhibition on ADR induced cell proliferation. The
experimental results showed that cell mortality rate of ADR
group, ADR combined veliparib group increased significantly
compared with the control group. At the same time, mortality
rate of ADR combined with veliparib group was significantly
higher than that of ADR alone group. This suggested that the
use of veliparib made BEL-7404 cells to chemotherapeutic
drug susceptibility to ADR. Further proved cells DNA
damage of ADR group, ADR combined veliparib group were
significantly increased, DNA damage level of ADR combined
veliparib group was significantly higher than that of ADR
alone group. Results of protein levels showed cytochrome c
release of mitochondrion in ADR combined with veliparib
group was higher than that of control group and ADR alone
group. Cytochrome c release was a key event in apoptosis of
mitochondrial dependentlisl, Therefore, MTT, cell apoptosis
and single cell gel electrophoresis experiment results
showed in this experimental system, veliparib aggravate the
damage tumor cells DNA induced ADR through DNA repair
inhibition of PARP-l, and promote the inducing effect of
ADR on mitochondrial dependent apoptosis.
In conclusion, the results of this study showed that, 5-20
[J. mol/L concentration of veliparib combined with routine
dosage of ADR could inhibit the proliferation of liver cancer
cell line BEL-7404 and induce its apoptosis. This study
on veliparib as sensitizer for chemotherapy ADR provide
a preliminary experimental basis for adjuvant treatment
of liver cancer. With the deep research on veliparib as
adjuvant chemotherapy, veliparib may play the key role for
treatment of various cancer in the future clinical.
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